The ability of low-dose TSA to promote tumor remissions as a single agent and its reliance on lymphocytes led us to speculate that HDAC inhibition alone might modulate endogenous anti-tumor T cell responses in TME, even in the absence of additional immunotherapy. Here, HDAC9 is linked to neoplasm.